RxDoctor Payments Data

Raj Rajan, MD

Cardiovascular Disease · Bradenton, FLNPI 1114971025

Payments from drug & device makers

$37,109in general payments, 2019–2025

Across 342 payments — averaging $108.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$17K
  • Amarin Pharma, Inc.$6K
  • Boston Scientific$6K
  • Amgen$3K
  • Novartis$999
  • Abbott$553
  • plus $4K from 33 others

What the payments were for

  • Speaking & faculty fees$7,20049%
  • Food & beverage$7,19449%
  • Education$3723%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,109 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$110,722
Medicare patients
277
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban162$149,938
XareltoRivaroxaban57$71,691
EntrestoSacubitril/Valsartan37$48,765
Diltiazem 12hr ErDiltiazem Hcl15$3,497
Isosorbide Mononitrate ErIsosorbide Mononitrate115$2,614
Nifedipine ErNifedipine87$2,451
Nebivolol Hcl24$2,429
Losartan Potassium161$1,867
Amiodarone Hcl18$1,622
Metoprolol Succinate126$1,517
ClopidogrelClopidogrel Bisulfate89$1,210
Rosuvastatin Calcium92$1,179
Amlodipine Besylate209$1,162
Metoprolol Tartrate161$1,141
Ranolazine ErRanolazine18$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$462$149,938162 claims
Johnson & JohnsonXarelto$309$71,69157 claims
NovartisEntresto$999$48,76537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →